Brokerages predict that Theravance Biopharma, Inc. (NASDAQ:TBPH) will announce sales of $3.72 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Theravance Biopharma’s earnings, with the lowest sales estimate coming in at $3.23 million and the highest estimate coming in at $4.20 million. Theravance Biopharma reported sales of $5.69 million during the same quarter last year, which indicates a negative year-over-year growth rate of 34.6%. The company is expected to announce its next quarterly earnings report on Monday, February 26th.

On average, analysts expect that Theravance Biopharma will report full-year sales of $3.72 million for the current fiscal year, with estimates ranging from $12.95 million to $14.90 million. For the next fiscal year, analysts anticipate that the business will report sales of $30.15 million per share, with estimates ranging from $14.19 million to $46.10 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Theravance Biopharma.

Several research firms recently weighed in on TBPH. ValuEngine cut shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Tuesday. Cantor Fitzgerald reiterated a “buy” rating and issued a $55.00 target price on shares of Theravance Biopharma in a research note on Tuesday, November 7th. Robert W. Baird reiterated a “sell” rating and issued a $22.00 target price on shares of Theravance Biopharma in a research note on Wednesday, November 1st. Zacks Investment Research upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating and set a $37.00 target price for the company in a research note on Tuesday, October 10th. Finally, Evercore ISI assumed coverage on shares of Theravance Biopharma in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $45.00 target price for the company. Four analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $41.86.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/11/14/3-72-million-in-sales-expected-for-theravance-biopharma-inc-tbph-this-quarter.html.

In other Theravance Biopharma news, SVP Frank Pasqualone purchased 4,000 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The stock was purchased at an average price of $26.34 per share, with a total value of $105,360.00. Following the completion of the transaction, the senior vice president now directly owns 213,180 shares of the company’s stock, valued at approximately $5,615,161.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Bradford J. Shafer sold 14,670 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total transaction of $451,395.90. Following the completion of the transaction, the executive vice president now directly owns 134,327 shares of the company’s stock, valued at approximately $4,133,241.79. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. increased its holdings in shares of Theravance Biopharma by 46.1% during the second quarter. Russell Investments Group Ltd. now owns 21,465 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 6,777 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Theravance Biopharma by 3.6% during the second quarter. BlackRock Inc. now owns 3,638,838 shares of the biopharmaceutical company’s stock worth $144,972,000 after buying an additional 126,393 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in shares of Theravance Biopharma by 3.3% during the first quarter. Parametric Portfolio Associates LLC now owns 14,090 shares of the biopharmaceutical company’s stock worth $519,000 after buying an additional 456 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Theravance Biopharma by 5.8% during the first quarter. Geode Capital Management LLC now owns 330,280 shares of the biopharmaceutical company’s stock worth $12,160,000 after buying an additional 18,177 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its holdings in shares of Theravance Biopharma by 11.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 162,608 shares of the biopharmaceutical company’s stock worth $5,988,000 after buying an additional 17,136 shares in the last quarter. 84.55% of the stock is owned by institutional investors.

Shares of Theravance Biopharma (NASDAQ:TBPH) opened at $28.28 on Tuesday. The company has a current ratio of 7.53, a quick ratio of 7.21 and a debt-to-equity ratio of 1.21. Theravance Biopharma has a one year low of $23.15 and a one year high of $43.44.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.